Berapa harga GenSight Biologics S.A. (SIGHT)

Harga GenSight Biologics S.A. (SIGHT) adalah $0.12122506

Apa kapitalisasi pasar GenSight Biologics S.A. (SIGHT)

Kapitalisasi pasar GenSight Biologics S.A. (SIGHT) adalah $19.76M

Pendapatan GenSight Biologics S.A. (SIGHT)

GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.

Tahun	Laba	Mengubah
Tidak cukup data untuk tanggal yang disediakan.

Tahun

Laba

Mengubah

Tidak cukup data untuk tanggal yang disediakan.

Perusahaan	Laba	Perbedaan Laba	Negara
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$1.61B	-	AU
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Perusahaan

Laba

Perbedaan Laba

Negara